Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an ...

Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Basel: Roche has announced that the company has received approval from the European Commission for Columvi (glofitamab) in ...

A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing ...

Global Bispecific Trispecific Antibodies Market Size Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, April 04, ...

Summit Therapeutics Inc. (SMMT) - 1100% jump in weekly message volume The biopharma company saw a sharp rise in retail ...